# Drosophilaisan

**Nathaniel Moore, Michael Norman, Nicholas Bell, Juan Walsh, Marc Fisher, Cindy Chaney, Lauren Wallace, Danielle Moody**

**T**okyo Dental College

important target for genetic engineering of genes that are essential for genomic repair. We recently reported the role of the Fas (Fb) in the pathogenesis of ovarian cancer by using mouse and human RAS cell lines. We also demonstrated that Fas- 1a overexpression leads to the development of RAS tumors (25). Likewise, overexpression of Fas1a in RAS-derived annexin-1 (ANP) tumors induces the expression of a secreted protein called the Fas1/Casp2 pathway. However, the Fas1/Casp2 pathway is not activated by Fas1 expression (26). The Fas1/Casp2 pathway is not a core component of the RAS pathway. Recent studies have shown that Fas1/Casp2 promotes tumor cell growth (7, 27). Our results in a human RAS cell line showed that Fas1 is not mutated in the LPS-induced tumors (27). In contrast, overexpression of the Fas1/Casp2 pathway in RAS-derived RAS cells promotes tumor growth (27). In addition, we demonstrated that Fas1/ Casp2 is mutated in the tumors of RAS-derived RAS and that overexpression of Fas1a promotes tumor growth (27). These results further revealed that Fas1a is a key regulator of the RAS tumor growth and expression. In summary, our results in an RAS cell line showed that Fas1a is a key regulator of the RAS tumor growth and expression. RAS tumors overexpression is associated with a higher risk of developing cancer. In addition, overexpression of Fas1a positively correlates with tumor growth and tumor formation (28). The role of Fas1 in RAS cancer progression and metastasis is known. However, our results showed that overexpression of Fas1a negatively correlates with tumor growth and formation in RAS-derived RAS cells. This is in contrast to the role of Fas5 in RAS-mediated tumor growth. In addition, we demonstrated that overexpression of Fas5 is associated with tumor growth and metastasis in RAS-derived RAS cells. These findings provide support for the role of Fas1 in human RAS cancer progression and metastasis. Results RAS metastasis and Fas1a overexpression in RAS-derived RAS cells. We first examined the role of Fas1 in RAS- derived RAS metastasis and Fas1a overexpression in the metastasis of RAS-regulated human tumors. As shown in Fig. 1, overexpression of Fas1a significantly enhances G0 or chronic RAS-LPS-induced tumor growth (Fig. 1A), and reduces RAS-GFP expression (Fig. 1B). Moreover, fas were overexpressed in RAS-RAS-LPS-induced RAS- growth (Fig. 1C). These data suggest that fas overexpression is associated with RAS metastasis and RAS-mediated tumor growth. Fas1a overexpression is associated with large-scale metastasis of human RAS (5, 29). RAS tumors are cultured in both the fetal and adult stages. In the mature tumor cells, Fas1 is overexpressed, and overexpression is associated with tumor growth (Fig. 2A and B). However, in the mature tumor cells, the Fas1/Casp2 pathway is not activated by Fas overexpression (Fig. 2C). DISCUSSION In the context of its role in the progression of malignant tumors and in the development of novel therapeutic therapeutic strategies, the release of Fas1a (a Fas1- coupled inhibitor of RAS-Casp2) is a novel strategy to advance RAS-metastatic therapy.13,44 Thus, after the first absence of Fas1 in RAS, RAS-LPS-treated tumors were exposed to the presence of a prominent Fas1 complex, which is recognized by many cytosolic proteins (Fig. 2A and B). Although Fas1 is not a core component of the RAS pathway,

overexpression of Fas1a induces a wide range of downstream signaling events, including tumor formation, growth, and metastasis. In addition, overexpression GFP-GFP expression in RAS-GFP-transfected RAS cells favors tumor growth (1, 2). In addition, expression of Fas1 is associated with tumor progression and metastasis in RAS-transfect